NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP
Cardinal Health, Inc. CAH
18 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY17 YEARS OF DIVIDEND GROWTH
Revenue · FY2024
$222.6B
▼ 1.9% vs FY2023
Dividend streak
17 yrs
Raised every year since 2008
EPS · FY24
$6.45
Dividend / sh · FY24
$2.02
Payout · FY24
32%
ROE · FY24
—
Net margin · FY24
0.7%
Dividend coverage
3.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 222.6B
Revenue, FY2024 · full 18-year series below
Revenue
Net income
1 cents of every revenue dollar became profit this year.
Per share
USD 6.45
Diluted EPS, FY2024
EPS
Dividend
Earnings covered the dividend 3.2 times — the rest stayed in the company.
Profitability
—
Return on equity, FY2024
ROE
Operating margin1.0%
Net margin0.7%
Return on assets3.2%
Returned to shareholders
USD 1.3B
returned in FY2024 · dividends + net buybacks
Dividends paidUSD 494.0M
Net buybacksUSD 765.0M
Share of profit80.7%
Consecutive raises17 years
USD 494.0M in dividends and USD 765.0M in buybacks — 81% of the year's profit went back to shareholders.
Growth
+7.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.1%
+7.8%
+8.1%
+5.6%
Net income
+2.5%
+6.1%
EPS, diluted
+5.9%
+9.0%
Dividend / share
+1.0%
+1.0%
+4.0%
+7.3%
Returned to shareholders
−6.9%
+6.5%
−1.7%
+7.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 53.1B
total assets, end of FY2024
Total assetsUSD 53.1B
EquityUSD -2.8B
CashUSD 3.9B
Gross debtUSD 8.0B
Net debtUSD 4.1B
Current ratio0.94×
Net debt stands at -148% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
222.6
226.8
205.0
181.3
162.5
152.9
145.5
136.8
130.0
121.5
102.5
91.1
101.1
107.6
102.6
98.5
96.0
87.4
Operating income $B
2.3
1.2
0.8
−0.6
0.5
−4.1
2.1
0.1
2.1
2.5
2.2
1.9
1.0
1.8
1.5
1.3
1.3
1.4
EBITDA $B
3.1
2.0
1.4
0.1
1.3
−3.2
3.1
1.2
2.8
3.1
2.6
2.3
1.4
2.1
1.8
1.6
1.5
1.6
Income tax $B
0.5
0.3
0.3
0.2
−0.3
−0.1
0.4
−0.5
0.6
0.8
0.8
0.6
0.6
0.6
0.6
0.6
0.4
0.4
Net income $B
1.6
0.9
0.3
−0.9
0.6
−3.7
1.4
0.3
1.3
1.4
1.2
1.2
0.3
1.1
1.0
0.6
1.2
1.3
EPS, diluted $
6.45
3.45
1.26
−3.37
2.08
−12.61
4.53
0.81
4.03
4.32
3.62
3.38
0.97
3.06
2.72
1.77
3.18
3.57
Dividend / sh $
2.02
2.00
1.98
1.96
1.94
1.92
1.91
1.85
1.80
1.55
1.37
1.21
1.02
0.86
0.78
0.70
0.56
0.48
Payout %
32
59
159
−60
94
−15
42
227
45
36
38
36
106
28
29
39
17
13
ROE %
·
·
·
−173.4
34.1
−91.1
22.0
4.0
19.3
22.3
19.2
18.8
5.5
17.7
17.2
9.2
14.0
16.8
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
70 of 70
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed